Efficacy, safety and tolerability data shared at hematology meeting
First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease
Physicians shares insights about screening, supportive care and potential therapies in development
A 12-year-old patient and others in clinical trial are cured of sickle cell disease thanks to half-match donors
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The short answer from Rabi Hanna, MD
The short answer from Rabi Hanna, MD
Percutaneous vertebral augmentation proves safe and effective
Advertisement
Advertisement